CONTACT: Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 email@example.com Argot Partners Susan Kim 212-600-1902 firstname.lastname@example.org Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 email@example.com
WATERTOWN, Mass., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Guy Macdonald, Tetraphase's President and Chief Executive Officer, will present at the Oppenheimer 26 th Annual Healthcare Conference on Tuesday, December 8 th at 4:30 p.m. Eastern Time at the Westin Grand Central Hotel in New York City. A live audio webcast of the Oppenheimer presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days. About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, a late-stage broad-spectrum antibiotic, and two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.